Reference : Platelet-rich plasma versus hyaluronic acid to treat tendinopathies
Scientific congresses and symposiums : Paper published in a journal
Human health sciences : Orthopedics, rehabilitation & sports medicine
Platelet-rich plasma versus hyaluronic acid to treat tendinopathies
Kaux, Jean-François mailto [Université de Liège - ULiège > Département des sciences de la motricité > Médecine physique, réadaptation et traumatologie du sport >]
Robertjot, Mathieu []
SAMSON, Antoine [Centre Hospitalier Universitaire de Liège - CHU > > Service de médecine de l'appareil locomoteur >]
Croisier, Jean-Louis mailto [Université de Liège - ULiège > Département des sciences de la motricité > Kinésithérapie générale et réadaptation >]
European Journal of Sports Medicine
European Federation of Sports Medicine Associations (EFSMA)
Supplement 1
Abstract book - 10th EFSMA congress
Yes (verified by ORBi)
10th EFSMA congress
16-18 November 2017
[en] INTRODUCTION: The treatment of patellar tendinopathies could be difficult. This is the reason why new treatments have been developed, among which platelet rich plasma (PRP) injections. Some clinical series have previously evaluated the effect of PRP in the treatment of proximal patellar tendinopathies. Recent systematic review concluded that PRP could be recommend as a treatment in such indication (1). Recently, the viscoelastic properties of hyaluronic acid (HA) on liquid connective tissue have been proposed for the treatment of tendinopathies (2). Some fundamental studies show encouraging results on HA’s ability to promote tendon gliding and reduce adhesion as well as to improve tendon architectural organisation. Some observations also support its use in a clinical setting to improve pain and function.
PURPOSE: We aimed to compare the effect of PRP injection versus two injections of HA after three months on patients who have a proximal patellar tendinopathy.
METHODS: Thirtythree sportsmen with proximal patellar tendinopathies being not relieved after minimum three months of normal physiotherapy treatments where included. Eighteen of them (group 1) have received a leukocyte poor PRP injection (obtained using an aphaeresis machine (3)) and the other fifteen (group 2) two HA injections, all of them have benefited of standardized rehabilitation. Concerning the evaluation of the pathology, algofunctional tests (visual analogic scale (VAS), pressure algometer, IKDC score, VISAP score), isokinetic (associated to VAS) along with the patellar tendon ultrasonography (US) have been realized over three times (preinjection, after 6 weeks, after 3 months
RESULTS: The results of VAS (p<0,01), algometric scores (p<0,01), IKDC scores (p<0,01) and VISAP (p<0,01) show a considerable improvement in the two groups, but not for the US findings. For the group 1, isokinetic tests show significative results for the hamstrings in C60°/s with an improvement of maximum peak torque (p=0,01) for the pathological member, a diminution (p>0,05) for the healthy limb and during the analysis of the bilateral difference (p=0,0002). For the group 2, the improvement of quadriceps maximum peak torque in C240°/s is significant (p>0,01) for the pathological knee after 6 weeks post injections only. The VAS associated with isokinetic tests decreases significantly for all contraction modes after three months of study.
CONCLUSIONS: Both PRP and HA can improve the symptoms of proximal patellar tendinopathy, even if the results are slightly better in the PRP group.
Andia I et al., Plateletrich plasma in the conservative treatment of painful tendinopathy: a systematic review and metaanalysis of controlled studies. Br Med Bull. 2014 Jun;110(1):99115.
Kaux JF et al., Hyaluronic acid and tendon lesions. Muscles Ligaments Tendons J. 2016 Feb 13;5(4):2649.
Kaux JF et al. Using platelet rich plasma to treat jumper's knees: Exploring the effect of a second closely timed infiltration. J Sci Med Sport. 2016 Mar;19(3):2004.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Platelet-rich plasma versus hyaluronic acid to treat tendinopathies.pdfAuthor postprint2.19 MBRequest copy

Additional material(s):

File Commentary Size Access
Open access
156-740-1-PB.pdf1.62 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.